Warner Bros. Discovery Shares Rise as Newsom Pushes Settlement in $110 Billion Merger Fight 
Arm Holdings Q1 Earnings Beat Estimates, Strong Q2 Outlook Fails to Lift ARM Stock 
SpaceX Wins $1.6 Billion U.S. Space Force Launch Contracts for Falcon 9 Missions Through 2027 
Sony Eyes $1.3 Billion Tamron Acquisition as Lens Maker Reviews Offer 
Meta-backed research finds exposure to ‘untrustworthy’ social media is rare. The fine print is less reassuring 
Amazon Q2 Earnings Beat Estimates as AWS AI Growth Surges, But Q3 Revenue Forecast Disappoints 
Russia Charges Telegram Founder Pavel Durov With Facilitating Terrorism, Seeks International Arrest 
Roblox Stock Drops 16% as Q3 Bookings Forecast Misses Expectations 
Japan Earthquake Disrupts Auto and Chip Supply Chains 
Toyota First-Half Global Sales and Production Decline on Weak China Demand, RAV4 Transition 
Same sparkle, different story: how lab-grown diamonds are transforming the market 
Standard Chartered Beats Profit Forecasts as First-Half Earnings Rise 9% 
Colgate-Palmolive Reaffirms 2026 Sales Outlook Despite Weak North America Demand 
T-Mobile Executives Reportedly Oppose $300 Billion Deutsche Telekom Merger 
Qualcomm Stock Falls as Weak Q4 Forecast, Apple Revenue Decline Overshadow AI Data Center Growth 
Robinhood Q2 Earnings Beat Estimates, But HOOD Stock Falls as Investors Question Profit Quality 
GSK Unveils $2.52 Billion Cost-Cutting Plan to Accelerate Drug Pipeline 
BRIDGEWATER, N.J., May 01, 2018 -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company focused on the unmet needs of patients with rare diseases, today announced that Will Lewis, President and Chief Executive Officer of Insmed, will present at the Deutsche Bank 43rd Annual Health Care Conference in Boston, MA on Tuesday, May 8, 2018 at 4:10 p.m. EDT.
The presentation will be webcast live and can be accessed by visiting the investor relations section of the company's website at www.insmed.com. The webcast will be archived for a period of 90 days following the conclusion of the live event.
About Insmed
Insmed Incorporated is a global biopharmaceutical Company focused on the unmet needs of patients with rare diseases. The Company’s lead product candidate is ALIS, which is in late-state development for adult patients with treatment refractory NTM lung disease caused by MAC, which is a rare and often chronic infection that is capable of causing irreversible lung damage and can be fatal. Insmed's earlier-stage clinical pipeline includes INS1007, a novel oral reversible inhibitor of dipeptidyl peptidase 1 with therapeutic potential in non-cystic fibrosis bronchiectasis and other inflammatory diseases, and INS1009, an inhaled nanoparticle formulation of a treprostinil prodrug that may offer a differentiated product profile for rare pulmonary disorders, including pulmonary arterial hypertension. For more information, visit www.insmed.com.
Contact:
Blaine Davis
Insmed Incorporated
(908) 947-2841
[email protected]
